Compare · ATYR vs GILD
ATYR vs GILD
Side-by-side comparison of aTyr Pharma Inc. (ATYR) and Gilead Sciences Inc. (GILD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ATYR and GILD operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD is the larger of the two at $161.88B, about 2102.9x ATYR ($77.0M).
- Over the past year, ATYR is down 75.8% and GILD is up 22.6% - GILD leads by 98.4 points.
- GILD has hit the wire 8 times in the past 4 weeks while ATYR has been quiet.
- GILD has more recent analyst coverage (25 ratings vs 9 for ATYR).
- Company
- aTyr Pharma Inc.
- Gilead Sciences Inc.
- Price
- $0.79+0.29%
- $130.38-2.48%
- Market cap
- $77.0M
- $161.88B
- 1M return
- +0.34%
- -5.67%
- 1Y return
- -75.81%
- +22.62%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2015
- 1992
- News (4w)
- 0
- 8
- Recent ratings
- 9
- 25
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Latest ATYR
- SEC Form DEFA14A filed by aTyr Pharma Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by aTyr Pharma Inc.
- SEC Form DEF 14A filed by aTyr Pharma Inc.
- SEC Form PRE 14A filed by aTyr Pharma Inc.
- SEC Form 10-K filed by aTyr Pharma Inc.
- aTyr Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- aTyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate Update
- aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference
- President and CEO Shukla Sanjay converted options into 10,375 shares and sold $3,655 worth of shares (3,745 units at $0.98), increasing direct ownership by 5% to 153,553 units (SEC Form 4)
Latest GILD
- Gilead Sciences to Release First Quarter 2026 Financial Results on Thursday, May 7, 2026
- Gilead Receives All Required Regulatory Approvals for the Acquisition of Arcellx and Extends Tender Offer
- SEC Form 4 filed by Dickinson Andrew D
- SEC Form 4 filed by Mercier Johanna
- PEPFAR and The Global Fund Make Additional Investment in Gilead's Lenacapavir for HIV Prevention to Further Expand Access
- Tempus Announces Strategic Collaboration with Gilead to Advance Oncology R&D Through RWE
- EQT Life Sciences to exit minority stake in Tubulis via sale to Gilead Sciences for up to USD 5.0 billion
- Gilead to Acquire Tubulis Adding Potentially Best-in-Class Antibody-Drug Conjugate and Next Generation Platform to Further Strengthen Oncology Pipeline
- Gilead Extends Tender Offer to Acquire Arcellx
- SEC Form 4 filed by O'Day Daniel Patrick